Investor Presentation

6 Corbus Pipeline: Early and Late Stage Programs Lenabasum CRB-4001 Pre-clinical library (over 600 drug candidates) Multi-system Inflammatory Genetic Systemic Sclerosis Dermatomyositis Systemic Lupus Erythematosus Cystic Fibrosis Preclinical Diseases with organ-specific fibrosis (e.g., liver, lung, heart, kidney) Goal: 1-2 new Phase 1 programs each year starting in 2020 Phase 1 Targeting 2019 Phase 2 NIH to run Phase 2 study Phase 3 Promising Pipeline Launch Targeting 2021

View entire presentation